Advanced chemoembolization by anti-angiogenic calcium-phosphate ceramic microspheres targeting the vascular heterogeneity of cancer xenografts

Anticancer Research

Volumn 35, Issue 9, 2015, Pages 4757-4764

  Emoto, Makoto ^a   Yoshihisa, Hajime ^b   Yano, Kyoko ^c   Choijamts, Batsuren ^a   Tsugu, Hitoshi ^c   Tachibana, Katsuro ^c   Aizawa, Mamoru ^b  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b MEIJI UNIVERSITY   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

Author keywords

Antiangiogenic therapy; Carcinosarcoma; Ceramics; Chemoembolization; Drug delivery system (DDS); Microsphere; TNP 470; Uterine sarcoma; Vascular heterogeneity

Indexed keywords

CALCIUM PHOSPHATE CERAMIC MICROSPHERE; FUMAGILLOL CHLOROACETYLCARBAMATE; MICROSPHERE; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CALCIUM PHOSPHATE; CYCLOHEXANE DERIVATIVE; O-(CHLOROACETYLCARBAMOYL)FUMAGILLOL; SESQUITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER THERAPY; CARCINOGENESIS; CHEMICAL COMPOSITION; CHEMOEMBOLIZATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RADIATION RESPONSE; THERAPY; TISSUE NECROSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UTERUS SARCOMA; ANIMAL; CERAMICS; DRUG SCREENING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; SCANNING ELECTRON MICROSCOPY; THERAPEUTIC USE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CALCIUM PHOSPHATES; CERAMICS; CHEMOEMBOLIZATION, THERAPEUTIC; CRYSTALLIZATION; CYCLOHEXANES; HUMANS; MICE, NUDE; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SESQUITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939608854     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Acharya S, Hensley ML, Montag AC and Fleming GF: Rare uterine cancers. Lancet Oncol 6: 961-971, 2005.
2. Emoto M, Charnock-Jones DS, Licence D, Ishiguro M, Kawai M, Yanaihara A, Saito T, Hachisuga T, Iwasaki H, Kawarabayashi T and Smith SK: Localisation of the VEGF and angiopoietin genes in uterine carcinosarcoma. Gynecol Oncol 95: 474-482, 2004.
3. Checkley D, Tessier JJ, Kendrew J, Waterton JC, and Wedge SR Use of Dynamic Contrast-enhanced MRI to Evaluate Acute Treatment with ZD6474, A VEGF Signalling Inhibitor, inPC-3 Prostate Tumours. Br J Cancer 89 1889-1895, 2003
4. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12: 323-334, 2012.
5. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, and Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555-557, 1990.
6. Zhang Y, Griffith EC, Sage J, Jacks T, and Liu JO. Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci USA 97: 6427-6432, 2000.
7. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, and Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 94: 6099-6103, 1997.
8. Yanase T, Tamura M, Fujita K, Kodama S, and Tanaka K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 53: 2566-2570, 1993.
9. Yoshida T, Kaneko Y, Tsukamoto A, Han K, Ichinose M, and Kimura S. Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP-470. Cancer Res 58: 3751-3756, 1998.
10. Inoue K, Chikazawa M, Fukata S, Yoshikawa C, and Shuin T. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastatic human transitional cell carcinoma in the urinary bladder. Clin Cancer Res 8: 2389-2398, 2002.
11. Inoue K, Chikazawa M, Fukata S, Yoshikawa C, and Shuin T. Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. Clin Cancer Res 9: 886-899, 2003.
12. Nahari D, Satchi-Fainaro R, Chen M, Mitchell I, Task LB, Liu Z, Kihneman J, Carroll AB, Terada LS, and Nwariaku FE. Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer. Mol Cancer Ther 6: 1329-1337, 2007.
13. Miura S, Emoto M, Matsuo Y, Kawarabayashi T, and Saku K. Carcinosarcoma-induced endothelial cells tube formation through KDR/FLK-1 is blocked by TNP-470. Cancer Lett 203: 45-50, 2004.
14. Emoto M, Ishiguro M, Iwasaki H, Kikuchi M, and Kawarabayashi T. Effect of Angiogenesis inhibitor TNP-470 on the growth, blood flow, and microvessel density in xenografts of human uterine carcinosarcoma in nude mice. Gynecol Oncol 89: 88-94, 2003.
15. Emoto M, Tachibana K, Iwasaki H, and Kawarabayashi T. Antitumor effect of TNP-470, an angiogenesis inhibitor, combined with ultrasound irradiation for human uterine sarcoma xenografts evaluated using contrast color Doppler ultrasound. Cancer Sci 98: 929-935, 2007.
16. Emoto M, Naganuma Y, Choijamts B, Ohno T, Yoshihisa H, Kanomata N, Kawarabayashi T, and Aizawa M: Novel chemoembolization using calcium-phosphate ceramic microsphere incorporating TNP-470, an anti-angiogenic agent. Cancer Sci 101: 984-990, 2010.
17. Aizawa M, Hanazawa T, Itatani K, Howell FS, and Kishioka A. Characterization of hydroxyapatite powders prepared by ultrasonic spray-pyrolysis technique. J Mater Sci 34: 2865-2873, 1999.
18. Aizawa M, Itatani K, Okada I. Synthesis of various apatites and porous coating of biocompatible calcium-phosphate films via spray-pyrolysis technique. Phosphorus Res Bull 20: 61-78, 2006.
19. Ohno T, and Aizawa M. Effect of the concentrations of the starting solution on the syntheses and powder properties of hollow tricalcium-phosphate microspheres by ultrasonic spray-pyrolysis technique. Key Engineer Mater 309-311: 235-238, 2006.
20. Aizawa M, Ohno T, Kanomata N, Yano K, and Emoto M. Antitumorigenesis of hollow calcium-phosphate microsphere loaded with anti-angiogenic agent. Key Engineer Mater 361-363: 1215-1218, 2008.
21. Emoto M, Iwasaki H, Oshima K, Kikuchi M, Kaneko Y, and Kawarabayashi T. Characteristics of rhabdomyosarcoma cell lines derived from uterine carcinosarcomas. Virchow Archiv 431: 249-256, 1997.
22. Matsumura Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies (Review). Adv Drug Deliv Rev 60: 899-914, 2008.
23. Kubo M, Kuwayama N, Hirashima Y, Takaku A, Ogawa T, and Endo S. Hydroxyapatite ceramics as a particulate embolic material: report of the physical properties of the hydroxyapatite particles and the animal study. AJNR 24: 1540-1544, 2003.
24. Kubo M, Kuwayama N, Hirashima Y, Takaku A, Ogawa T, and Endo S Hydroxyapatite ceramics as a particulate embolic material: Report of the clinical experience AJNR 24: 1545-1547, 2003
25. Petersen LK, and Narashimhan B. Combinational design of biomaterials for drug delivery: opportunities and challenges. Expert Opin Drug Deliv 5: 837-846, 2008.
26. Kawata M, Uchida H, Itatani K, Okada I, Koda S, and Aizawa M. Development of porous ceramics with well-controlled porosities and pore sizes from apatite fibers and their evaluations. J Mater Sci Mater Med 15: 817-823, 2004.
27. Aizawa M, Porter AE, Best SM, and Bonfield M. Ultrastructural observation of single-crystal apatite fibres. Biomaterials 26: 3427-3433, 2005.
28. Morisue H, Matsumoto M, Chiba K, Matsumoto H, Toyama Y, Aizawa M, Kanzawa N, Fujimi TJ, Uchida H, and Okada I. Novel apatite fiber scaffolds can promote three-dimensional proliferation of osteoblasts in rodent bone regeneration models. J Biomed Mater Res A 90: 811-818, 2009.
29. Yuan H, Kurashina K, de Bruijn JD, Li Y, de Groot K, and Zhang X. A preliminary study on osteoinduction of two kinds of calcium-phosphate ceramics. Biomaterials 20: 1799-1806, 1999.
30. Nagayama M, Takeuchi H, Doi Y. Comparison of carbonate apatite and b-tricalcium phosphate (resorbable calcium phosphates) implanted subcutaneously into the back of rats. Dent Mater J 25: 219-225, 2006.
31. Victor SP, and Sampath Kumar TS. BCP ceramics microspheres as drug delivery carriers: synthesis, characterization, and doxycycline release. J Mater Sci Mater Med 19: 283-290, 2008.
32. Kawashita M, Shineha R, Kim HM, Kokubo T, Inoue Y, Araki N, Nagata Y, Hiraoka M, and Sawada Y. Preparation of ceramic microspheres for in situ radiotherapy of deep-seated cancers. Biomaterials 24: 2955-2963, 2003.
33. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91: 1071-1121, 2011.
34. Naganuma Y, Choijamts B, Shirota K, Nakajima K, Ogata S, Miyamoto S, Kawarabayashi T, and Emoto M. Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts. Cancer Sci 102: 1545-1552, 2011.